The abstract is read at the publisher; the summary is JClub's.
Proteomic pathway clustering of pretreatment metastatic cutaneous melanoma identifies three ICI subtypes, including an immune-enriched group linked to better dual PD-1/CTLA-4 outcomes.
- Why it matters: Predictive biomarkers for combined PD-1/CTLA-4 blockade in metastatic melanoma are limited, especially those grounded in tumor biology before treatment.
- What they did: The study profiled 208 FFPE specimens using TMT-based proteomics, RNA sequencing, and targeted/low-pass whole-genome sequencing, then used pathway clustering and machine-learning to define and validate subtype signatures.
- The result: Subtypes stratified progression-free survival after dual therapy in Discovery (P=0.01) and Validation 1 (P=0.02), with immune-enriched tumors showing the highest responder fractions (74% and 73%) and a 127-protein classifier predicting 3-year progression/death (AUC 0.79).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.